Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Officially Designates Second Notified Body Under The MDR: TÜV SÜD Enters Center Stage

Executive Summary

TÜV SÜD, headquartered in Germany, is the second notified body to be officially designated under the EU MDR. Is this good news going to significantly lessen medtech industry’s concerns over delays in accessing the new, tougher regulatory system for medical technology, with time running seriously short?

You may also be interested in...



IVDR And Brexit Outlook For IVD Firms: EU Themes To The Fore At Asian Medtech Associations Reg Networking

This month’s Asian Medtech Associations Regulatory Networking discussions is split into two parts, the first being a guest presentation on EU themes, specifically a UK Brexit outlook and an update on the progress of the EU IVDR, which comes into full effect on 26 May 2022. Both have potentially far-reaching effects for Asian and other global medtech markets. Part two will feature AHWP and Asean updates, as usual. This editorial feature is hosted by Medtech Insight, along with the Asia Regulatory and Quality Consultancy (ARQon) and the Asia Regulatory Professionals Association (ARPA).

EU MDR One Year Out: Reg Demands Forcing European Business Closures

The impact of high regulatory demands on the innovation potential of medtech companies in Europe was a sub-theme of last week’s MedTech Forum in Paris. But it’s not a theoretical risk, for coinciding with the Forum was a decision by Swiss company Jossi Holding to close its orthopedics subsidiary.   

99 Days Until MDR: Time Is Running Out For Medtech As Risky, Volatile Future Looms

The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.

Topics

UsernamePublicRestriction

Register

MT125140

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel